Novo Nordisk (NVO) said Wednesday it will cut costs as it faces increasing competition from Eli Lilly (LLY) and generic ...

Novo Nordisk A/S’s sales showed the weakest growth in four years as the Danish drugmaker loses ground to Eli Lilly & Co. in ...

Maziar Mike Doustdar will take the helm as CEO tomorrow, with the firm facing tough questions from investors about how it can stay competitive.

The US president has flagged higher-than-expected tariffs of up to 250 per cent on drug imports, which is a potential blow to ...

Sales of Novo Nordisk’s diabetes drugs including Ozempic slowed to grow at 8 per cent year on year in the first half, down sharply from its rate last year, as the company loses market share to rival ...

Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...

Eli Lilly and Company is gearing up for its second quarter earnings report this Thursday, before the market opens. The pharmaceutical giant has witnessed significant revenue boosts from its ...

While a substantial portion of pipeline assets are externally sourced, many Big Pharmas are tapping into incubators and ...

Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting earnings this Thursday before the bell. Here’s what ...

Eris Lifesciences is using its growing insulin business to position itself as a serious contender in India’s fast-expanding ...

Eli Lilly's stock is lagging the S&P 500 since April, potentially allowing a catch-up trade if results impress. Medicare may ...